What is considered cardiotoxicity of anthracyclines in animal studies
Corrigendum in: /10.3892/or.2020.7717
- Authors:
- Nikolaos Georgiadis
- Konstantinos Tsarouhas
- Ramin Rezaee
- Haritini Nepka
- George E.N. Kass
- Jean‑Lou C.M. Dorne
- Dimitrios Stagos
- Konstantinos Toutouzas
- Demetrios A. Spandidos
- Dimitrios Kouretas
- Christina Tsitsimpikou
-
Affiliations: European Chemicals Agency, 00150 Helsinki, Finland, Department of Cardiology, University Hospital of Larissa, 41334 Larissa, Greece, Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, 9177948564 Mashhad, Iran, Department of Pathology, University Hospital of Larissa, 41334 Larissa, Greece, European Food Safety Authority, I-43126 Parma, Italy, Department of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece, First Department of Cardiology, Hippokration Hospital, Medical School, University of Athens, 11527 Athens, Greece, Laboratory of Virology, Medical School, University of Crete, 71003 Heraklion, Greece - Published online on: July 14, 2020 https://doi.org/10.3892/or.2020.7688
- Pages: 798-818
-
Copyright: © Georgiadis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al ESC Scientific Document Group, : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 37:2768–2801. 2016. View Article : Google Scholar : PubMed/NCBI | |
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 27:911–939. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pardo Sanz A and Zamorano JL: ‘Cardiotoxicity’: time to define new targets? Eur Heart J. 41:1730–1732. 2020. View Article : Google Scholar : PubMed/NCBI | |
Park CJ, Branch ME, Vasu S and Melendez GC: The role of cardiac MRI in animal models of cardiotoxicity: hopes and challenges. J Cardiovasc Transl Res. Apr 4–2020.(Epub ahead of print). View Article : Google Scholar | |
Sobczuk P, Czerwinska M, Kleibert M and Cudnoch-Jedrzejewska A: Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. May 30–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
Hashemzaei M, Karami SP, Delaramifar A, Sheidary A, Tabrizian K, Rezaee R, Shahsavand S, Arsene AL, Tsatsakis AM and Mohammad S: Anticancer effects of co-administration of daunorubicin and resveratrol in MOLT-4, U266 B1 and RAJI cell lines. Farmacia. 64:36–42. 2016. | |
Iranshahi M, Barthomeuf C, Bayet-Robert M, Chollet P, Davoodi D, Piacente S, Rezaee R and Sahebkar A: Drimane-type sesquiterpene coumarins from ferula gummosa fruits enhance doxorubicin uptake in doxorubicin-resistant human breast cancer cell line. J Tradit Complement Med. 4:118–125. 2014. View Article : Google Scholar : PubMed/NCBI | |
Schwarz ER, Pollick C, Dow J, Patterson M, Birnbaum Y and Kloner RA: A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 39:216–223. 1998. View Article : Google Scholar : PubMed/NCBI | |
Robert J: Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls. Cell Biol Toxicol. 23:27–37. 2007. View Article : Google Scholar : PubMed/NCBI | |
Germanakis I, Tsarouhas K, Fragkiadaki P, Tsitsimpikou C, Goutzourelas N, Champsas MC, Stagos D, Rentoukas E and Tsatsakis AM: Oxidative stress and myocardial dysfunction in young rabbits after short term anabolic steroids administration. Food Chem Toxicol. 61:101–105. 2013. View Article : Google Scholar : PubMed/NCBI | |
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group, : Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI | |
Zacchigna S, Paldino A, Falcao-Pires I, Daskalopoulos EP, Dal Ferro M, Vodret S, Lesizza P, Cannatà A, Daniela Miranda-Silva D, et al: Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovasc Res. May 4–2020.(Epub ahead of print). View Article : Google Scholar | |
Liu J and Rigel DF: Echocardiographic examination in rats and mice. Methods Mol Biol. 573:139–155. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Lu X, Liu Z and Du K: Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. Int J Mol Med. 42:3415–3423. 2018.PubMed/NCBI | |
Tian XQ, Ni XW, Xu HL, Zheng L, ZhuGe DL, Chen B, Lu CT, Yuan JJ and Zhao YZ: Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. Int J Nanomedicine. 12:7103–7119. 2017. View Article : Google Scholar : PubMed/NCBI | |
Andreadou I, Mikros E, Ioannidis K, Sigala F, Naka K, Kostidis S, Farmakis D, Tenta R, Kavantzas N, Bibli SI, et al: Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol. 69:4–16. 2014. View Article : Google Scholar : PubMed/NCBI | |
Oliveira MS, Melo MB, Carvalho JL, Melo IM, Lavor MSI, Gomes DA, de Goes AM and Melo MM: Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer Sci Ther. 5:52–57. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hydock DS, Lien CY and Hayward R: Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther. 14:59–67. 2009. View Article : Google Scholar : PubMed/NCBI | |
Fernandez-Fernandez A, Carvajal DA, Lei T and McGoron AJ: Chemotherapy-induced changes in cardiac capillary permeability measured by fluorescent multiple indicator dilution. Ann Biomed Eng. 42:2405–2415. 2014. View Article : Google Scholar : PubMed/NCBI | |
Todorova VK, Kaufmann Y and Klimberg VS: Increased efficacy and reduced cardiotoxicity of metronomic treatment with cyclophosphamide in rat breast cancer. Anticancer Res. 31:215–220. 2011.PubMed/NCBI | |
Vasić M, Lončar-Turukalo T, Tasić T, Matić M, Glumac S, Bajić D, Popović B and Japundžić-Žigon N: Cardiovascular variability and β-ARs gene expression at two stages of doxorubicin-induced cardiomyopathy. Toxicol Appl Pharmacol. 362:43–51. 2019. View Article : Google Scholar : PubMed/NCBI | |
Mathias LMBS, Alegre PHC, Dos Santos IOF, Bachiega T, Figueiredo AM, Chiuso-Minicucci F, Fernandes AA, Bazan SGZ, Minicucci MF, Azevedo PS, et al: Euterpe oleracea Mart. (Açai) supplementation attenuates acute doxorubicin-induced cardiotoxicity in rats. Cell Physiol Biochem. 53:388–399. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Chen L, Wang T, Jiang X, Zhang H, Li P, Lv B and Gao X: Ginsenoside Rg3 antagonizes adriamycin-induced cardiotoxicity by improving endothelial dysfunction from oxidative stress via upregulating the Nrf2-ARE pathway through the activation of akt. Phytomedicine. 22:875–884. 2015. View Article : Google Scholar : PubMed/NCBI | |
Arozal W, Watanabe K, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Suzuki K, Kodama M and Aizawa Y: Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol. 62:1776–1783. 2010. View Article : Google Scholar : PubMed/NCBI | |
Argun M, Üzüm K, Sönmez MF, Özyurt A, Derya K, Çilenk KT, Unalmış S, Pamukcu Ö, Baykan A, Narin F, et al: Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. Anatol J Cardiol. 16:234–241. 2016.PubMed/NCBI | |
Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S and Sener G: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 43:195–205. 2009. View Article : Google Scholar : PubMed/NCBI | |
Razmaraii N, Babaei H, Mohajjel Nayebi A, Assadnassab G, Ashrafi Helan J and Azarmi Y: Crocin treatment prevents doxorubicin-induced cardiotoxicity in rats. Life Sci. 157:145–151. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gziri MM, Pokreisz P, De Vos R, Verbeken E, Debiève F, Mertens L, Janssens SP and Amant F: Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment. J Pharmacol Exp Ther. 346:362–369. 2013. View Article : Google Scholar : PubMed/NCBI | |
Oliveira LF, O'Connell JL, Carvalho EE, Pulici ECC, Romano MMD, Maciel BC and Simões MV: Comparison between radionuclide ventriculography and echocardiography for quantification of left ventricular systolic function in rats exposed to doxorubicin. Arq Bras Cardiol. 108:12–20. 2017.PubMed/NCBI | |
Carvalho PB, Gonçalves AF, Alegre PH, Azevedo PS, Roscani MG, Bergamasco CM, Modesto PN, Fernandes AA, Minicucci MF, Paiva SA, et al: Pamidronate attenuates oxidative stress and energetic metabolism changes but worsens functional outcomes in acute doxorubicin-induced cardiotoxicity in rats. Cell Physiol Biochem. 40:431–442. 2016. View Article : Google Scholar : PubMed/NCBI | |
Stewart LK, Smoak P, Hydock DS, Hayward R, O'Brien K, Lisano JK, Boeneke C, Christensen M and Mathias A: Milk and kefir maintain aspects of health during doxorubicin treatment in rats. J Dairy Sci. 102:1910–1917. 2019. View Article : Google Scholar : PubMed/NCBI | |
Polegato BF, Minicucci MF, Azevedo PS, Carvalho RF, Chiuso-Minicucci F, Pereira EJ, Paiva SA, Zornoff LA, Okoshi MP, Matsubara BB, et al: Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cell Physiol Biochem. 35:1924–1933. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lee KH, Cho H, Lee S, Woo JS, Cho BH, Kang JH, Jeong YM, Cheng XW and Kim W: Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity. Int J Cardiol. 232:40–47. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cheah HY, Šarenac O, Arroyo JJ, Vasić M, Lozić M, Glumac S, Hoe SZ, Hindmarch CCT, Murphy D, Kiew LV, et al: Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats. Nanotoxicology. 11:210–222. 2017. View Article : Google Scholar : PubMed/NCBI | |
Li X, Xu G, Wei S, Zhang B, Yao H, Chen Y, Liu W, Wang B, Zhao J and Gao Y: Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling. BMC Complement Altern Med. 19:3602019. View Article : Google Scholar : PubMed/NCBI | |
Dundar HA, Kiray M, Kir M, Kolatan E, Bagriyanik A, Altun Z, Aktas S, Ellidokuz H, Yilmaz O, Mutafoglu K, et al: Protective effect of acetyl-L-carnitine against doxorubicin-induced cardiotoxicity in wistar albino rats. Arch Med Res. 47:506–514. 2016. View Article : Google Scholar : PubMed/NCBI | |
Barış VO, Gedikli E, Yersal N, Müftüoğlu S and Erdem A: Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: Echocardiographical and histological findings. Amino Acids. 51:1649–1655. 2019. View Article : Google Scholar : PubMed/NCBI | |
Lu PP, Ma J, Liang XP, Guo CX, Yang YK, Yang KQ, Shen QM, Ma LH and Zhou XL: Xinfuli improves cardiac function, histopathological changes and attenuate cardiomyocyte apoptosis in rats with doxorubicin-induced cardiotoxicity. J Geriatr Cardiol. 13:968–972. 2016.PubMed/NCBI | |
O'Connell JL, Romano MM, Campos Pulici EC, Carvalho EEV, de Souza FR, Tanaka DM, Maciel BC, Salgado HC, Fazan-Júnior R, Rossi MA, et al: Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. Exp Toxicol Pathol. 69:213–219. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chang SA, Lim BK, Lee YJ, Hong MK, Choi JO and Jeon ES: A novel angiotensin type I receptor antagonist, Fimasartan, prevents Doxorubicin-induced cardiotoxicity in rats. J Korean Med Sci. 30:559–568. 2015. View Article : Google Scholar : PubMed/NCBI | |
Teng LL, Shao L, Zhao YT, Yu X, Zhang DF and Zhang H: The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. J Int Med Res. 38:940–948. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kim YH, Kim M, Park SM, Kim SH, Lim SY, Ahn JC, Song WH and Shim WJ: Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. Echocardiography. 29:720–728. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kondru SK, Potnuri AG, Allakonda L and Konduri P: Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. Mol Cell Biochem. 441:77–88. 2018. View Article : Google Scholar : PubMed/NCBI | |
Moriyama T, Kemi M and Horie T: Elevated cardiac 3-deoxyglucosone, a highly reactive intermediate in glycation reaction, in doxorubicin-induced cardiotoxicity in rats. Pathophysiology. 23:237–242. 2016. View Article : Google Scholar : PubMed/NCBI | |
Burdick J, Berridge B and Coatney R: Strain echocardiography combined with pharmacological stress test for early detection of anthracycline induced cardiomyopathy. J Pharmacol Toxicol Methods. 73:15–20. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ammar HI, Sequiera GL, Nashed MB, Ammar RI, Gabr HM, Elsayed HE, Sareen N, Rub EA, Zickri MB and Dhingra S: Comparison of adipose tissue- and bone marrow-derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats. Stem Cell Res Ther. 6:1482015. View Article : Google Scholar : PubMed/NCBI | |
Calvé A, Haddad R, Barama SN, Meilleur M, Sebag IA and Chalifour LE: Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training. Am J Physiol Heart Circ Physiol. 302:H2048–H2057. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shen LJ, Lu S, Zhou YH, Li L, Xing QM and Xu YL: Developing a rat model of dilated cardiomyopathy with improved survival. J Zhejiang Univ Sci B. 17:975–983. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wu Z, Zhao X, Miyamoto A, Zhao S, Liu C, Zheng W and Wang H: Effects of steroidal saponins extract from Ophiopogon japonicus root ameliorates doxorubicin-induced chronic heart failure by inhibiting oxidative stress and inflammatory response. Pharm Biol. 57:176–183. 2019. View Article : Google Scholar : PubMed/NCBI | |
Shoukry HS, Ammar HI, Rashed LA, Zikri MB, Shamaa AA, Abou Elfadl SG, Rub EA, Saravanan S and Dhingra S: Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. PLoS One. 12:e01815352017. View Article : Google Scholar : PubMed/NCBI | |
Niu QY, Li ZY, Du GH and Qin XM: (1)H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model. J Pharm Biomed Anal. 118:338–348. 2016. View Article : Google Scholar : PubMed/NCBI | |
Boutagy NE, Wu J, Cai Z, Zhang W, Booth CJ, Kyriakides TC, Pfau D, Mulnix T, Liu Z, Miller EJ, et al: In vivo reactive oxygen species detection with a novel positron emission tomography tracer, 18F-DHMT, allows for early detection of anthracycline-induced cardiotoxicity in rodents. JACC Basic Transl Sci. 3:378–390. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lee PJ, Rudenko D, Kuliszewski MA, Liao C, Kabir MG, Connelly KA and Leong-Poi H: Survivin gene therapy attenuates left ventricular systolic dysfunction in doxorubicin cardiomyopathy by reducing apoptosis and fibrosis. Cardiovasc Res. 101:423–433. 2014. View Article : Google Scholar : PubMed/NCBI | |
da Silva MG, Mattos E, Camacho-Pereira J, Domitrovic T, Galina A, Costa MW and Kurtenbach E: Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases. Exp Clin Cardiol. 17:101–109. 2012.PubMed/NCBI | |
Mao C, Hou X, Wang B, Chi J, Jiang Y, Zhang C and Li Z: Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats. Stem Cell Res Ther. 8:182017. View Article : Google Scholar : PubMed/NCBI | |
Deng B, Wang JX, Hu XX, Duan P, Wang L, Li Y and Zhu QL: Nkx2.5 enhances the efficacy of mesenchymal stem cells transplantation in treatment heart failure in rats. Life Sci. 182:65–72. 2017. View Article : Google Scholar : PubMed/NCBI | |
Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, Burdy JY, Fabbro-Peray P, Laprade M, Bali JP, et al: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 329:39–51. 2003. View Article : Google Scholar : PubMed/NCBI | |
Sun R, Wang J, Zheng Y, Li X, Xie T, Li R, Liu M, Cao Y, Lu L, Zhang Q, et al: Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy. Exp Ther Med. 13:1900–1906. 2017. View Article : Google Scholar : PubMed/NCBI | |
Guerra J, De Jesus A, Santiago-Borrero P, Roman-Franco A, Rodríguez E and Crespo MJ: Plasma nitric oxide levels used as an indicator of doxorubicin-induced cardiotoxicity in rats. Hematol J. 5:584–588. 2005. View Article : Google Scholar : PubMed/NCBI | |
Gao Y, Yang H, Fan Y, Li L, Fang J and Yang W: Hydrogen-rich saline attenuates cardiac and hepatic injury in doxorubicin rat model by inhibiting inflammation and apoptosis. Mediators Inflamm. 2016:13203652016. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Tang Y, Xiang Y, Xie YQ, Huang XH and Zhang YC: Shengmai injection improved doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. BioMed Res Int. 2015:9526712015.PubMed/NCBI | |
Li H, Mao Y, Zhang Q, Han Q, Man Z, Zhang J, Wang X, Hu R, Zhang X, Irwin DM, et al: Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy. J Ethnopharmacol. 192:459–470. 2016. View Article : Google Scholar : PubMed/NCBI | |
Leontyev S, Schlegel F, Spath C, Schmiedel R, Nichtitz M, Boldt A, Rübsamen R, Salameh A, Kostelka M, Mohr FW, et al: Transplantation of engineered heart tissue as a biological cardiac assist device for treatment of dilated cardiomyopathy. Eur J Heart Fail. 15:23–35. 2013. View Article : Google Scholar : PubMed/NCBI | |
Merlet N, Piriou N, Rozec B, Grabherr A, Lauzier B, Trochu JN and Gauthier C: Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. PLoS One. 8:e647112013. View Article : Google Scholar : PubMed/NCBI | |
Ozkanlar Y, Aktas MS, Turkeli M, Erturk N, Oruc E, Ozkanlar S, Kirbas A, Erdemci B and Aksakal E: Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity. Int J Cardiol. 173:519–521. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hong YM, Lee H, Cho MS and Kim KC: Apoptosis and remodeling in adriamycin-induced cardiomyopathy rat model. Korean J Pediatr. 60:365–372. 2017. View Article : Google Scholar : PubMed/NCBI | |
Teraoka K, Hirano M, Yamaguchi K and Yamashina A: Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail. 2:373–378. 2000. View Article : Google Scholar : PubMed/NCBI | |
Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G and George J: Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J. 27:1876–1883. 2006. View Article : Google Scholar : PubMed/NCBI | |
Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, Wang Y, Sooryakumar D, Yu SJ, Pomper MG, et al: Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Mol Imaging. 7:132–138. 2008. View Article : Google Scholar : PubMed/NCBI | |
Yu Q, Li Q, Na R, Li X, Liu B, Meng L, Liutong H, Fang W, Zhu N and Zheng X: Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol Cell Biochem. 387:279–285. 2014. View Article : Google Scholar : PubMed/NCBI | |
Bai J, Gu R, Wang B, Zhang N, Kang L and Xu B: Overexpression of integrin-linked kinase improves cardiac function in a rat model of doxorubicin-induced chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi. 42:225–229. 2014.(In Chinese). PubMed/NCBI | |
Lu XL, Tong YF, Liu Y, Xu YL, Yang H, Zhang GY, Li XH and Zhang HG: Gαq protein carboxyl terminus imitation polypeptide GCIP-27 improves cardiac function in chronic heart failure rats. PLoS One. 10:e01210072015. View Article : Google Scholar : PubMed/NCBI | |
Wachtman LM, Browning MD, Bedja D, Pin S and Gabrielson KL: Validation of the use of long-term indwelling jugular catheters in a rat model of cardiotoxicity. J Am Assoc Lab Anim Sci. 45:55–64. 2006.PubMed/NCBI | |
Zhang J, Zhang L, Wu Q, Liu H and Huang L: Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats. Mol Med Rep. 7:628–632. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S, Aslam S, Wang PW and Xu J: Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther. 21:367–374. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ha JW, Kang SM, Pyun WB, Lee JY, Ahn MY, Kang WC, Jeon TJ, Chung N, Lee JD and Cho SH: Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model. Yonsei Med J. 46:73–77. 2005. View Article : Google Scholar : PubMed/NCBI | |
Emanuelov AK, Shainberg A, Chepurko Y, Kaplan D, Sagie A, Porat E, Arad M and Hochhauser E: Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage. Biochem Pharmacol. 79:180–187. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lim SC: Interrelation between expression of ADAM 10 and MMP 9 and synthesis of peroxynitrite in doxorubicin induced cardiomyopathy. Biomol Ther (Seoul). 21:371–380. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hydock DS, Lien CY, Schneider CM and Hayward R: Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc. 40:808–817. 2008. View Article : Google Scholar : PubMed/NCBI | |
Xiang P, Deng HY, Li K, Huang G-Y, Chen Y, Tu L, Ng PC, Pong NH, Zhao H, Zhang L, et al: Dexrazoxane protects against doxorubicin-induced cardiomyopathy: Upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol. 63:343–349. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kenk M, Thackeray JT, Thorn SL, Dhami K, Chow BJ, Ascah KJ, DaSilva JN and Beanlands RS: Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol. 17:254–263. 2010. View Article : Google Scholar : PubMed/NCBI | |
Katona M, Boros K, Sántha P, Ferdinandy P, Dux M and Jancsó G: Selective sensory denervation by capsaicin aggravates adriamycin-induced cardiomyopathy in rats. Naunyn Schmiedebergs Arch Pharmacol. 370:436–443. 2004. View Article : Google Scholar : PubMed/NCBI | |
Hydock DS, Parry TL, Jensen BT, Lien CY, Schneider CM and Hayward R: Effects of endurance training on combined goserelin acetate and doxorubicin treatment-induced cardiac dysfunction. Cancer Chemother Pharmacol. 68:685–692. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX and Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther. 20:85–91. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hydock DS, Lien CY, Jensen BT, Schneider CM and Hayward R: Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther. 10:47–57. 2011. View Article : Google Scholar : PubMed/NCBI | |
Koh E, Nakamura T and Takahashi H: Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J. 68:163–167. 2004. View Article : Google Scholar : PubMed/NCBI | |
Carresi C, Musolino V, Gliozzi M, Maiuolo J, Mollace R, Nucera S, Maretta A, Sergi D, Muscoli S, Gratteri S, et al: Anti-oxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: Role of autophagy and c-kitposCD45negCD31neg cardiac stem cell activation. J Mol Cell Cardiol. 119:10–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ma H, Kong J, Wang YL, Li JL, Hei NH, Cao XR, Yang JJ, Yan WJ, Liang WJ, Dai HY, et al: Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. Oncotarget. 8:24548–24563. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang XJ, Cao XQ, Zhang CS and Zhao Z: 17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes. Mol Med Rep. 15:2695–2702. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sun XP, Wan LL, Yang QJ, Huo Y, Han YL and Guo C: Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. Arch Pharm Res. 40:875–883. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhu HJ, Han ZY, He SF, Jin S-Y, Xu S-J, Fang X-D and Zhang Y: Specific MicroRNAs comparisons in hypoxia and morphine preconditioning against hypoxia-reoxgenation injury with and without heart failure. Life Sci. 170:82–92. 2017. View Article : Google Scholar : PubMed/NCBI | |
Croteau E, Tremblay S, Gascon S, Dumulon-Perreault V, Labbé SM, Rousseau JA, Cunnane SC, Carpentier AC, Bénard F and Lecomte R: [(11)C]-Acetoacetate PET imaging: A potential early marker for cardiac heart failure. Nucl Med Biol. 41:863–870. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ikegami E, Fukazawa R, Kanbe M, Watanabe M, Abe M, Watanabe M, Kamisago M, Hajikano M, Katsube Y and Ogawa S: Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death. Circ J. 71:1815–1820. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC and Wu JC: Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 142:396–403.e3. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tang DX, Zhao HP, Pan CS, Liu YY, Wei XH, Yang XY, Chen YY, Fan JY, et al: QiShenYiQi pills, a compound Chinese medicine, ameliorates doxorubicin-induced myocardial structure damage and cardiac dysfunction in rats. Evid Based Complement Alternat Med: eCAM. 2013:4805972013. View Article : Google Scholar | |
Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M and Kalyanaraman B: Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol. 34:208–214. 2008. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Xu W, Xiong Y, Du G and Qin X: Evaluations of the effect of HuangQi against heart failure based on comprehensive echocardiography index and metabonomics. Phytomedicine. 50:205–212. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, et al: Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 48:1438–1447. 2006. View Article : Google Scholar : PubMed/NCBI | |
Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, et al: Sex differences in anthracycline-induced cardiotoxicity: The benefits of estrogens. Heart Fail Rev. 24:915–925. 2019. View Article : Google Scholar : PubMed/NCBI | |
Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 97:2869–2879. 2003. View Article : Google Scholar : PubMed/NCBI | |
Blanter JB and Frishman WH: The preventive role of angiotensin converting enzyme inhibitors/angiotensin-II receptor blockers and β-adrenergic blockers in anthracycline- and trastuzumab-induced cardiotoxicity. Cardiol Rev. 27:256–259. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sharkey LC, Radin MJ, Heller L, Rogers LK, Tobias A, Matise I, Wang Q, Apple FS and McCune SA: Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. Toxicol Appl Pharmacol. 273:47–57. 2013. View Article : Google Scholar : PubMed/NCBI | |
Georgiadis N, Tsarouhas K, Tsitsimpikou C, Vardavas A, Rezaee R, Germanakis I, Tsatsakis A, Stagos D and Kouretas D: Pesticides and cardiotoxicity. Where do we stand? Toxicol Appl Pharmacol. 353:1–14. 2018. View Article : Google Scholar : PubMed/NCBI | |
Vasilaki F, Tsitsimpikou C, Tsarouhas K, Germanakis I, Tzardi M, Kavvalakis M, Ozcagli E, Kouretas D and Tsatsakis AM: Cardiotoxicity in rabbits after long-term nandrolone decanoate administration. Toxicol Lett. 241:143–151. 2016. View Article : Google Scholar : PubMed/NCBI | |
Achar S, Rostamian A and Narayan SM: Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 106:893–901. 2010. View Article : Google Scholar : PubMed/NCBI |